athenahealth risk/reward balanced at current levels, says Jefferies. Jefferies analyst Sean Dodge raised his price target for athenahealth to $160 from $130 saying he views the risk/reward as balanced at current share levels despite Elliott Management’s $160-plus offer. athenahealth does not appear to be a willing seller, Dodge tells investors in a research note. He also does not see any likely strategic suitors, meaning that if a deal gets done, it will be to a financial buyer. The analyst’s valuation work caps upside of athenahealth shares at $170 and downside at $120. Dodge keeps a Hold rating on the name.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.